(PLSE) Pulse Biosciences - Ratings and Ratios
Nanosecond Pulse, Electroportation, Bioelectrics, Tissue, Surgical
PLSE EPS (Earnings per Share)
PLSE Revenue
Description: PLSE Pulse Biosciences
Pulse Biosciences Inc (NASDAQ:PLSE) is a US-based company operating in the Health Care Equipment sub-industry. The companys common stock is listed on NASDAQ.
To evaluate the stocks potential, we need to examine key performance indicators (KPIs) and economic drivers. The companys market capitalization stands at approximately $1.087 billion. Given the negative Return on Equity (RoE) of -65.27%, its clear that the company is currently unprofitable. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, further indicates that the company is not generating earnings.
To deconstruct the problem, we need to identify the key drivers of the companys financial performance. As a healthcare equipment company, Pulse Biosciences success is likely tied to the development and commercialization of its products, as well as the overall demand for healthcare equipment. Key economic drivers may include the growth rate of the healthcare industry, the competitive landscape, and the companys ability to innovate and bring new products to market.
From a trading perspective, the stocks beta of 1.601 indicates that it is relatively volatile compared to the broader market. This volatility, combined with the stocks current price of $15.68 and Average True Range (ATR) of 0.63, suggests that traders should be prepared for potential price swings. To engineer a solution, we need to focus on identifying optimal trading opportunities, potentially by analyzing the stocks price action and identifying key levels of support and resistance.
PLSE Stock Overview
| Market Cap in USD | 1,012m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2016-05-18 |
PLSE Stock Ratings
| Growth Rating | 16.7% |
| Fundamental | 32.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -31.3% |
| Analyst Rating | - |
PLSE Dividends
Currently no dividends paidPLSE Growth Ratios
| Growth Correlation 3m | 5.7% |
| Growth Correlation 12m | -57.8% |
| Growth Correlation 5y | -8.1% |
| CAGR 5y | 130.54% |
| CAGR/Max DD 3y | 2.34 |
| CAGR/Mean DD 3y | 5.51 |
| Sharpe Ratio 12m | -1.27 |
| Alpha | 0.13 |
| Beta | 0.883 |
| Volatility | 76.90% |
| Current Volume | 299.4k |
| Average Volume 20d | 128.2k |
| Stop Loss | 15.8 (-5%) |
| Signal | 1.02 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-68.0m TTM) > 0 and > 6% of Revenue (6% = 149.8k TTM) |
| FCFTA -0.30 (>2.0%) and ΔFCFTA 51.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3974 % (prev 1223 %; Δ 2751 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.37 (>3.0%) and CFO -44.5m > Net Income -68.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (67.3m) change vs 12m ago 17.66% (target <= -2.0% for YES) |
| Gross Margin 33.93% (prev 34.77%; Δ -0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 3.11% (prev 4.30%; Δ -1.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -40.53
| (A) 0.82 = (Total Current Assets 108.2m - Total Current Liabilities 8.98m) / Total Assets 120.3m |
| (B) -3.55 = Retained Earnings (Balance) -426.5m / Total Assets 120.3m |
| warn (B) unusual magnitude: -3.55 — check mapping/units |
| (C) -0.89 = EBIT TTM -71.4m / Avg Total Assets 80.3m |
| (D) -27.05 = Book Value of Equity -426.4m / Total Liabilities 15.8m |
| Total Rating: -40.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.11
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -3.99% = -1.99 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.08 = 2.50 |
| 5. Debt/Ebitda -0.12 = -2.50 |
| 6. ROIC - WACC -77.74% = -12.50 |
| 7. RoE -65.27% = -2.50 |
| 8. Rev. Trend 34.98% = 2.62 |
| 9. EPS Trend 29.78% = 1.49 |
What is the price of PLSE shares?
Over the past week, the price has changed by +11.38%, over one month by +6.12%, over three months by +8.55% and over the past year by -18.39%.
Is Pulse Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PLSE is around 13.27 USD . This means that PLSE is currently overvalued and has a potential downside of -20.25%.
Is PLSE a buy, sell or hold?
What are the forecasts/targets for the PLSE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22 | 32.2% |
| Analysts Target Price | 22 | 32.2% |
| ValueRay Target Price | 14.9 | -10.5% |
Last update: 2025-09-10 04:45
PLSE Fundamental Data Overview
CCE Cash And Equivalents = 106.3m USD (Cash And Short Term Investments, last quarter)
P/S = 60.229
P/B = 9.6867
Beta = 1.682
Revenue TTM = 2.50m USD
EBIT TTM = -71.4m USD
EBITDA TTM = -70.3m USD
Long Term Debt = 6.79m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.46m USD (from shortTermDebt, last quarter)
Debt = 8.24m USD (Calculated: Short Term 1.46m + Long Term 6.79m)
Net Debt = -98.1m USD (from netDebt column, last quarter)
Enterprise Value = 914.0m USD (1.01b + Debt 8.24m - CCE 106.3m)
Interest Coverage Ratio = unknown (Ebit TTM -71.4m / Interest Expense TTM 0.0)
FCF Yield = -3.99% (FCF TTM -36.5m / Enterprise Value 914.0m)
FCF Margin = -1461 % (FCF TTM -36.5m / Revenue TTM 2.50m)
Net Margin = -2725 % (Net Income TTM -68.0m / Revenue TTM 2.50m)
Gross Margin = 33.93% ((Revenue TTM 2.50m - Cost of Revenue TTM 1.65m) / Revenue TTM)
Tobins Q-Ratio = -2.14 (set to none) (Enterprise Value 914.0m / Book Value Of Equity -426.4m)
Interest Expense / Debt = 5.80% (Interest Expense 478.0k / Debt 8.24m)
Taxrate = 21.0% (US default)
NOPAT = -71.4m (EBIT -71.4m, no tax applied on loss)
Current Ratio = 12.05 (Total Current Assets 108.2m / Total Current Liabilities 8.98m)
Debt / Equity = 0.08 (Debt 8.24m / last Quarter total Stockholder Equity 104.5m)
Debt / EBITDA = -0.12 (Net Debt -98.1m / EBITDA -70.3m)
Debt / FCF = -0.23 (Debt 8.24m / FCF TTM -36.5m)
Total Stockholder Equity = 104.2m (last 4 quarters mean)
RoA = -56.57% (Net Income -68.0m, Total Assets 120.3m )
RoE = -65.27% (Net Income TTM -68.0m / Total Stockholder Equity 104.2m)
RoCE = -64.32% (Ebit -71.4m / (Equity 104.2m + L.T.Debt 6.79m))
RoIC = -68.51% (NOPAT -71.4m / Invested Capital 104.2m)
WACC = 9.23% (E(1.01b)/V(1.02b) * Re(9.27%)) + (D(8.24m)/V(1.02b) * Rd(5.80%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 5.54%
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -36.5m)
EPS Correlation: 29.78 | EPS CAGR: 0.0% | SUE: -0.48 | # QB: False
Revenue Correlation: 34.98 | Revenue CAGR: 0.0%
Additional Sources for PLSE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle